Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
1987 1
1989 3
1990 4
1991 4
1992 5
1993 2
1994 6
1995 12
1996 9
1997 7
1998 8
1999 5
2000 6
2001 2
2002 8
2003 12
2004 6
2005 13
2006 16
2007 7
2008 7
2009 10
2010 5
2011 5
2012 9
2013 6
2014 7
2015 6
2016 9
2017 4
2018 7
2019 9
2020 10
2021 9
2022 6
Text availability
Article attribute
Article type
Publication date

Search Results

231 results
Results by year
Filters applied: . Clear all
Page 1
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S; True North Study Group. Sandborn WJ, et al. Among authors: wolf dc. N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617. N Engl J Med. 2021. PMID: 34587385 Clinical Trial.
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
Sandborn WJ, Feagan BG, Wolf DC, D'Haens G, Vermeire S, Hanauer SB, Ghosh S, Smith H, Cravets M, Frohna PA, Aranda R, Gujrathi S, Olson A; TOUCHSTONE Study Group. Sandborn WJ, et al. Among authors: wolf dc. N Engl J Med. 2016 May 5;374(18):1754-62. doi: 10.1056/NEJMoa1513248. N Engl J Med. 2016. PMID: 27144850 Free article. Clinical Trial.
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P; ACCENT I Study Group. Hanauer SB, et al. Among authors: wolf dc. Lancet. 2002 May 4;359(9317):1541-9. doi: 10.1016/S0140-6736(02)08512-4. Lancet. 2002. PMID: 12047962 Clinical Trial.
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study.
Sandborn WJ, Feagan BG, Hanauer S, Vermeire S, Ghosh S, Liu WJ, Petersen A, Charles L, Huang V, Usiskin K, Wolf DC, D'Haens G. Sandborn WJ, et al. Among authors: wolf dc. J Crohns Colitis. 2021 Jul 5;15(7):1120-1129. doi: 10.1093/ecco-jcc/jjab012. J Crohns Colitis. 2021. PMID: 33438008 Free PMC article. Clinical Trial.
Infliximab maintenance therapy for fistulizing Crohn's disease.
Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Sands BE, et al. Among authors: wolf dc. N Engl J Med. 2004 Feb 26;350(9):876-85. doi: 10.1056/NEJMoa030815. N Engl J Med. 2004. PMID: 14985485 Free article. Clinical Trial.
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
Rutgeerts P, Gasink C, Chan D, Lang Y, Pollack P, Colombel JF, Wolf DC, Jacobstein D, Johanns J, Szapary P, Adedokun OJ, Feagan BG, Sandborn WJ. Rutgeerts P, et al. Among authors: wolf dc. Gastroenterology. 2018 Oct;155(4):1045-1058. doi: 10.1053/j.gastro.2018.06.035. Epub 2018 Aug 29. Gastroenterology. 2018. PMID: 29909019 Clinical Trial.
Reply.
Wolf DC. Wolf DC. Inflamm Bowel Dis. 2016 Sep;22(9):E32. doi: 10.1097/MIB.0000000000000878. Inflamm Bowel Dis. 2016. PMID: 27542140 No abstract available.
Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W; EXTEND Investigators, Kumar A, Lazar A, Camez A, Lomax KG, Pollack PF, D'Haens G. Rutgeerts P, et al. Among authors: wolf dc. Gastroenterology. 2012 May;142(5):1102-1111.e2. doi: 10.1053/j.gastro.2012.01.035. Epub 2012 Feb 8. Gastroenterology. 2012. PMID: 22326435 Clinical Trial.
231 results